GET DAILY SIGNALSPediatrix Medical Group (MD) Delivers Q3 2026 Beat and Raises Full-Year EBITDA Guidance
Key Takeaways
- Pediatrix Medical Group reported third-quarter 2026 net revenue of $501.4 million, up 1.7% year over year and slightly above analyst consensus estimates.
- Adjusted earnings per share (EPS) came in at $0.72, beating consensus estimates of roughly $0.65 and rising from $0.67 in the prior-year quarter.
- Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) reached $85.5 million, exceeding expectations even as it declined modestly from $87.3 million a year earlier.
- Management raised its full-year 2026 adjusted EBITDA guidance to a range of $290 million to $300 million, up from its prior $280 million to $300 million outlook.
- Same-unit revenue grew 0.6%, supported by a favorable shift in payor mix and higher patient acuity in neonatology.
- For additional context, explore Pediatrix Medical Group's Major News, Today's Price Move, Price Targets, and Forecast pages.
- Discover AI-driven trade ideas and market opportunities with Trending AI Robots.
Earnings Context and Why It Matters
As a leading physician-services group focused on prenatal, neonatal, and pediatric care, MD sits at the intersection of healthcare demand, reimbursement trends, and hospital relationships. Its quarterly results offer investors a read on patient volumes, payor mix, and the effectiveness of its revenue cycle management. The third quarter is particularly important because it follows a stretch of consistent earnings beats and comes as management works to improve operating efficiency while evaluating acquisitions in the women's and children's space. With shares having already climbed sharply in 2026, this report tests whether the company's margin and cash-collection momentum can justify the market's elevated expectations.
Reported Results
For the three months ended September 30, 2026, Pediatrix Medical Group reported net revenue of $501.4 million, a 1.7% increase from $492.9 million in the prior-year period. The result modestly exceeded consensus estimates of roughly $497 million. Growth reflected a 1.1% contribution from non-same-unit activity tied to recent acquisitions, partially offset by practice dispositions, plus a 0.6% increase in same-unit revenue.
On a GAAP basis, net income was $47.0 million, or $0.59 per diluted share, compared with $71.7 million, or $0.84 per share, a year earlier — a period that benefited from a $20.9 million gain on investments in divested businesses. Adjusted EPS, which excludes non-recurring items such as amortization, stock-based compensation, and restructuring costs, was $0.72, up from $0.67 in the prior-year quarter and above the consensus estimate of about $0.65.
Adjusted EBITDA was $85.5 million, compared with $87.3 million in the same quarter last year. The modest decline reflected higher expenses relative to revenue growth at existing units, partially offset by favorable contributions from recent acquisitions. Same-unit revenue from net reimbursement-related factors rose 0.3%, helped by a favorable payor mix, higher administrative fees from hospital partners, and increased patient acuity in neonatology. The percentage of services reimbursed by commercial and other non-government payors improved by 70 basis points. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Heading into the report, investor sentiment around Pediatrix Medical Group had been notably positive, with the stock up about 35% year to date versus a roughly 13% gain for the S&P 500. Analysts had maintained a generally neutral "Hold" stance, and the third-quarter beat on both revenue and adjusted EPS, combined with the upward revision to full-year adjusted EBITDA guidance, reinforced the narrative of improving operational execution. The key drivers of investor interpretation include sustained strength in cash collections, a favorable payor mix, and continued share repurchases, which reduced the weighted average share count and supported per-share results. The main offsetting factor is the modest year-over-year decline in adjusted EBITDA, which highlights lingering cost pressures.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most important signal is management's decision to raise full-year 2026 adjusted EBITDA guidance to a range of $290 million to $300 million, with the midpoint of $295 million sitting above consensus estimates near $289 million. This suggests the company expects its margin and reimbursement trends to remain supportive through the fourth quarter.
Investors should watch same-unit patient volume trends, particularly neonatal intensive care unit (NICU) days and hospital-based services, which have been a persistent source of softness. Reimbursement-related factors, including payor mix and administrative fees from hospital contracts, will also remain central, since these have driven much of the recent revenue growth even as volumes lag.
Cost management is another key area. Practice salaries and benefits remain the largest expense line, and any acceleration in clinical wage inflation could pressure margins. The company's continued focus on revenue cycle management (RCM) efficiency and its willingness to pursue acquisitions in adjacent women's and children's specialties will shape the growth trajectory. Finally, the balance sheet remains a source of optionality, with no borrowings under its revolving credit facility and an active share-repurchase program supporting per-share results. From what I see, these elements together point to a measured but constructive setup for the quarters ahead.
Using Tickeron’s AI Tools in Practice
In my own workflow, Tickeron’s AI Screener helps me quickly filter for stocks showing similar earnings momentum and technical setups within the healthcare sector. It lets me scan thousands of names using customizable criteria like industry, market cap, and AI-driven signals, which saves time when cross-checking results like these against peers. I find it especially useful for spotting patterns around earnings beats and guidance changes without manual digging through dozens of screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
MD in downward trend: price expected to drop as it breaks its higher Bollinger Band on October 22, 2026
MD broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 37 similar instances where the stock broke above the upper band. In 30 of the 37 cases the stock fell afterwards. This puts the odds of success at 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for MD moved out of overbought territory on October 27, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 21 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 60 cases where MD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 08, 2026. You may want to consider a long position or call options on MD as a result. In 64 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for MD just turned positive on October 08, 2026. Looking at past instances where MD's MACD turned positive, the stock continued to rise in 34 of 45 cases over the following month. The odds of a continued upward trend are 76%.
MD moved above its 50-day moving average on October 09, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for MD crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 83%.
Following a +5.24% 3-day Advance, the price is estimated to grow further. Considering data from situations where MD advanced for three days, in 195 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 134 of 198 cases where MD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. MD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 40 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.666) is normal, around the industry mean (204.282). P/E Ratio (13.573) is within average values for comparable stocks, (19.375). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.096) among similar stocks. P/S Ratio (1.119) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 85, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical services
Industry HospitalNursingManagement
Advertisement